Literature DB >> 21721161

The value of postoperative/preadjuvant chemotherapy computed tomography in the management of patients with ovarian cancer.

Evis Sala1, Lorenzo Mannelli, Kenji Yamamoto, Michelle Griffin, Nyree Griffin, Lee Grant, Richard Parker, Robin Crawford.   

Abstract

OBJECTIVE: The objectives of the study were to compare the operative assessment of residual disease with the postoperative computed tomography (CT) findings in patients with ovarian cancer who underwent primary surgical cytoreduction or interval debulking surgery to residual disease 1 cm or less and to assess the effect of potential prognostic factors on patient survival.
METHODS: Patients scheduled for surgery and with an available postoperative CT were eligible for the study. Images were retrospectively analyzed in consensus by 2 radiologists.A 5-point qualitative scoring system was used to evaluate the CT findings (1 = tumor definitely absent, 2 = tumor probably absent, 3 = tumor possibly present, 4 = tumor probably present, 5 = tumor definitely present).
RESULTS: Between September 2005 and December 2008, 206 consecutive patients were enrolled; 51 were eligible. In 30 cases (59%), the postoperative CT findings correlated with the surgeon's assessment of residual disease. For the univariate analyses, the only significant prognostic factors associated with overall survival were no residual disease versus residual disease of less than 1 cm as assessed by the surgeon (hazard ratio [HR], 3.06; 95%confidence interval [CI], 1.29--7.27; P = 0.011) and no residual disease versus residual disease greater than 1 cm on CT (HR, 2.57; 95% CI, 1.02--6.48; P = 0.045). The interaction of surgical residual disease and stage 3 was significant (HR, 3.40; 95% CI, 1.42--8.16;P = 0.006) in the multivariate Cox model.
CONCLUSIONS: There was only 59% correlation between the surgical assessment and post operative CT findings of residual disease in patients reported to have undergone optimal surgery. Stage and residual disease as assessed by the surgeon were significant prognostic factors for overall survival. The value for postoperative CT may lie in those cases with small-volume residual disease (visible but reported as G1 cm) at surgery.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21721161

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  5 in total

Review 1.  Unexpected gynecologic findings during abdominal surgery.

Authors:  Casey A Boyd; Taylor S Riall
Journal:  Curr Probl Surg       Date:  2012-04       Impact factor: 1.909

2.  A Molecularly Targeted Intraoperative Near-Infrared Fluorescence Imaging Agent for High-Grade Serous Ovarian Cancer.

Authors:  Kimberly Fung; Sai Kiran Sharma; Outi Keinänen; Kara Long Roche; Jason S Lewis; Brian M Zeglis
Journal:  Mol Pharm       Date:  2020-07-16       Impact factor: 4.939

3.  Incorporation of postoperative CT data into clinical models to predict 5-year overall and recurrence free survival after primary cytoreductive surgery for advanced ovarian cancer.

Authors:  Irene A Burger; Debra A Goldman; Hebert Alberto Vargas; Michael W Kattan; Changhon Yu; Lei Kou; Vaagn Andikyan; Dennis S Chi; Hedvig Hricak; Evis Sala
Journal:  Gynecol Oncol       Date:  2015-06-17       Impact factor: 5.482

4.  Correlation between Surgeon's assessment and radiographic evaluation of residual disease in women with advanced stage ovarian cancer reported to have undergone optimal surgical cytoreduction: An NRG Oncology/Gynecologic Oncology Group study.

Authors:  Ramez N Eskander; James Kauderer; Krishnansu S Tewari; Robert S Mannel; Robert E Bristow; David M O'Malley; Stephen C Rubin; Gretchen E Glaser; Chad A Hamilton; Keiichi Fujiwara; Warner K Huh; Frederick Ueland; Jean-Marie Stephan; Robert A Burger
Journal:  Gynecol Oncol       Date:  2018-03-15       Impact factor: 5.482

5.  Negative peritoneal washing cytology during interval debulking surgery predicts overall survival after neoadjuvant chemotherapy for ovarian cancer.

Authors:  Ayaka Iura; Morihito Takita; Aiko Kawano; Kazuaki Imai; Katsuyuki Konnai; Ryo Onose; Hisamori Kato
Journal:  J Gynecol Oncol       Date:  2018-05-04       Impact factor: 4.401

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.